←
Nick James5,299 posts
Nick James avatar✓

Nick James ✓

@Prof_Nick_James

Professor of Prostate and Bladder Cancer Research. Interests: from novel diagnostics to care of advanced disease and novel trial design

◷ Joined November 2012▧ 473 Photos and videos
Nick James avatar
Nick James@Prof_Nick_James·Jun 11

I never viewed it as in any way clinically relevant. It’s just a way of counting relapses consistently for trials. Threshold for imaging should be driven by the imaging you have available. Plus the relevant pathology etc.

Nick James avatar
Nick James@Prof_Nick_James·Jun 10

Would be interesting to do this piece of research. However, as per my previous comments, PROTEUS has compared 2 non standard approaches with no SOC control so hard to make sense of it.

Nick James avatar
Nick James@Prof_Nick_James·Jun 10

We have a number of professors of statistics on the author list and the paper has passed through peer statistical review at a high impact journal. I cannot comment on the specifics of the stats comments in this post but am confident in my co-authors’ knowledge in this area.

Rob Calvert avatar
⟳ Nick James retweeted
Rob Calvert@RobCalvert18·Jun 6

80% disease free survival at 1 year in bladder preserving Rx for MIBC using durvalumab and chemoradiotherapy. A significant step up from historical controls @Prof_Nick_James

Post attachmentPost attachmentPost attachmentPost attachment
Nick James avatar
Nick James@Prof_Nick_James·Jun 3

Exactly, only around half, yet still looks v similar to other groups’ TMT data. A subgroup had biopsy only and still did fine. We presented this at ESMO a while ago (but not published sorry)

Bradley Stish avatar
⟳ Nick James retweeted
Bradley Stish@DrStish·Jun 3

The data showing ⬇️outcomes when complete TURBT not done is almost certainly a surrogate marker of more advanced disease, which not surprisingly does worse. Appreciate @Prof_Nick_James sharing their experience. An extra procedure + creation of more hypoxia does seem low value.

David Cameron avatar
⟳ Nick James retweeted
David Cameron@David_Cameron·Jun 2

Today’s decision from the Health Secretary on prostate cancer screening is a missed opportunity - too timid, too slow, and lacking the bold ambition that we so desperately wanted to see. As I set out last week, I fundamentally disagree with the National Screening Committee’s advice on a future screening programme for prostate cancer, which is far too narrow. I strongly believe that if we are really to get on top of prostate cancer - the most common cancer in British men - then a proper, targeted screening programme for all those at higher risk is needed… and needed now. I welcome expanded provision of focal therapy, which I benefited from last year with my own cancer; this must be an urgent priority to make available across the NHS. And the recognition that more work is needed to screen at risk groups, such as black men, is important. But this was an opportunity for bold, decisive, life-saving action - action that would help save the heartache of too many families losing a loved-one to this disease. That, sadly, has been missed. We will continue the campaign to urge the Government to go further, faster and put in place a progressive policy that includes a proper screening programme for the most at-risk men.